Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVBP NASDAQ:DAWN NASDAQ:IPHA NASDAQ:NAGE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVBPArriVent BioPharma$20.19+3.4%$20.08$15.47▼$36.37$819.09M1.17266,234 shs477,296 shsDAWNDay One Biopharmaceuticals$7.55+1.9%$6.82$5.64▼$16.76$773.36M-1.251.31 million shs899,733 shsIPHAInnate Pharma$2.05-2.4%$2.02$1.29▼$3.51$188.97M0.227,157 shs16,208 shsNAGENiagen Bioscience$9.41+1.0%$10.37$3.13▼$14.69$750.48M2.21886,896 shs710,553 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVBPArriVent BioPharma+3.43%+5.60%+5.76%-14.16%-22.70%DAWNDay One Biopharmaceuticals+1.89%+0.53%+30.17%+5.01%-45.64%IPHAInnate Pharma-2.38%-3.53%-4.43%-4.65%-8.07%NAGENiagen Bioscience+0.97%-4.95%+0.11%-27.34%+172.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVBPArriVent BioPharma$20.19+3.4%$20.08$15.47▼$36.37$819.09M1.17266,234 shs477,296 shsDAWNDay One Biopharmaceuticals$7.55+1.9%$6.82$5.64▼$16.76$773.36M-1.251.31 million shs899,733 shsIPHAInnate Pharma$2.05-2.4%$2.02$1.29▼$3.51$188.97M0.227,157 shs16,208 shsNAGENiagen Bioscience$9.41+1.0%$10.37$3.13▼$14.69$750.48M2.21886,896 shs710,553 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVBPArriVent BioPharma+3.43%+5.60%+5.76%-14.16%-22.70%DAWNDay One Biopharmaceuticals+1.89%+0.53%+30.17%+5.01%-45.64%IPHAInnate Pharma-2.38%-3.53%-4.43%-4.65%-8.07%NAGENiagen Bioscience+0.97%-4.95%+0.11%-27.34%+172.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVBPArriVent BioPharma 3.00Buy$39.1493.87% UpsideDAWNDay One Biopharmaceuticals 3.13Buy$25.29234.91% UpsideIPHAInnate Pharma 3.33Buy$11.00436.59% UpsideNAGENiagen Bioscience 3.00Buy$13.4242.61% UpsideCurrent Analyst Ratings BreakdownLatest IPHA, NAGE, AVBP, and DAWN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/25/2025AVBPArriVent BioPharmaB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/18/2025DAWNDay One BiopharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$25.008/18/2025AVBPArriVent BioPharmaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/12/2025AVBPArriVent BioPharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.00 ➝ $42.008/12/2025AVBPArriVent BioPharmaCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.00 ➝ $33.008/11/2025NAGENiagen BioscienceHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$11.00 ➝ $12.008/6/2025DAWNDay One BiopharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$18.00 ➝ $16.008/6/2025DAWNDay One BiopharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$36.00 ➝ $25.007/28/2025IPHAInnate PharmaBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy7/22/2025AVBPArriVent BioPharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.007/10/2025AVBPArriVent BioPharmaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy$33.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVBPArriVent BioPharmaN/AN/AN/AN/A$7.65 per shareN/ADAWNDay One Biopharmaceuticals$131.16M5.90N/AN/A$4.99 per share1.51IPHAInnate Pharma$21.77M8.68N/AN/A$0.11 per share18.64NAGENiagen Bioscience$116.30M6.45$0.06 per share157.57$0.60 per share15.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVBPArriVent BioPharma-$80.49M-$4.02N/AN/AN/AN/A-55.40%-51.97%11/13/2025 (Estimated)DAWNDay One Biopharmaceuticals-$95.50M-$0.95N/AN/AN/A-50.63%-19.01%-16.99%10/29/2025 (Estimated)IPHAInnate Pharma-$53.53MN/A0.00∞N/AN/AN/AN/A9/17/2025 (Estimated)NAGENiagen Bioscience$8.55M$0.2144.81∞N/A15.24%23.12%15.53%N/ALatest IPHA, NAGE, AVBP, and DAWN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025AVBPArriVent BioPharma-$0.70-$0.90-$0.20-$0.90N/AN/A8/6/2025Q2 2025NAGENiagen Bioscience$0.02$0.04+$0.02$0.04$28.55 million$31.12 million8/5/2025Q2 2025DAWNDay One Biopharmaceuticals-$0.35-$0.29+$0.06-$0.29$35.55 million$33.91 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVBPArriVent BioPharmaN/AN/AN/AN/AN/ADAWNDay One BiopharmaceuticalsN/AN/AN/AN/AN/AIPHAInnate PharmaN/AN/AN/AN/AN/ANAGENiagen BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVBPArriVent BioPharmaN/A12.7412.74DAWNDay One BiopharmaceuticalsN/A9.659.53IPHAInnate Pharma2.522.602.60NAGENiagen BioscienceN/A3.883.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVBPArriVent BioPharma9.48%DAWNDay One Biopharmaceuticals87.95%IPHAInnate Pharma0.16%NAGENiagen Bioscience15.41%Insider OwnershipCompanyInsider OwnershipAVBPArriVent BioPharma18.58%DAWNDay One Biopharmaceuticals6.20%IPHAInnate Pharma31.89%NAGENiagen Bioscience9.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVBPArriVent BioPharma4040.57 million33.03 millionN/ADAWNDay One Biopharmaceuticals60102.43 million96.08 millionOptionableIPHAInnate Pharma22092.18 million62.79 millionNot OptionableNAGENiagen Bioscience12079.75 million72.26 millionN/AIPHA, NAGE, AVBP, and DAWN HeadlinesRecent News About These CompaniesNiagen Bioscience, Inc. (NASDAQ:NAGE) Receives $13.42 Consensus PT from BrokeragesSeptember 5 at 2:37 AM | americanbankingnews.comNiagen Bioscience, Inc. (NASDAQ:NAGE) Receives Average Rating of "Buy" from AnalystsSeptember 3 at 3:08 AM | marketbeat.comNiagen Bioscience, Inc.'s (NASDAQ:NAGE) Intrinsic Value Is Potentially 91% Above Its Share PriceSeptember 2, 2025 | uk.finance.yahoo.comNiagen Bioscience (NASDAQ:NAGE) Upgraded to Strong-Buy at Wall Street ZenSeptember 2, 2025 | marketbeat.comNiagen Bioscience (NASDAQ:NAGE) Stock Rating Lowered by Wall Street ZenAugust 26, 2025 | marketbeat.comNiagen Bioscience, Inc. 2025 Q2 - Results - Earnings Call PresentationAugust 19, 2025 | seekingalpha.comUnlocking Cellular Health With Science and TrustAugust 17, 2025 | latimes.comNiagen Bioscience (NASDAQ:NAGE) Rating Increased to Strong-Buy at Wall Street ZenAugust 17, 2025 | marketbeat.comHC Wainwright Expects Reduced Earnings for Niagen BioscienceAugust 16, 2025 | marketbeat.comHC Wainwright Issues Optimistic Outlook for NAGE EarningsAugust 15, 2025 | marketbeat.comNiagen: Imminent Trigger For A Significant Move Up (Technical Analysis)August 13, 2025 | seekingalpha.comStatutory Profit Doesn't Reflect How Good Niagen Bioscience's (NASDAQ:NAGE) Earnings AreAugust 13, 2025 | finance.yahoo.comNiagen Bioscience (NASDAQ:NAGE) Given New $12.00 Price Target at HC WainwrightAugust 12, 2025 | marketbeat.comQ2 EPS Forecast for Niagen Bioscience Increased by AnalystAugust 12, 2025 | marketbeat.comBreaking Down Niagen Bioscience: 4 Analysts Share Their ViewsAugust 11, 2025 | benzinga.comRoth Capital Cuts Earnings Estimates for Niagen BioscienceAugust 9, 2025 | marketbeat.comEarnings Beat: Niagen Bioscience, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their ModelsAugust 8, 2025 | finance.yahoo.comNiagen Bioscience (NASDAQ:NAGE) Shares Gap Up Following Strong EarningsAugust 8, 2025 | marketbeat.comNiagen Bioscience, Inc. (NASDAQ:NAGE) Given Average Recommendation of "Buy" by BrokeragesAugust 8, 2025 | marketbeat.comNiagen Bioscience Reports Strong Q2 Sales GrowthAugust 6, 2025 | msn.comNiagen Bioscience Inc (NAGE) Q2 2025: Everything You Need To Know Ahead Of EarningsAugust 6, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 2025Buffett’s Cash Hoard Signals Market Caution, Value Plays EmergeBy Gabriel Osorio-Mazilli | August 19, 20253 Big Dividend Plays With Strong Earnings to Back ThemBy Nathan Reiff | August 11, 2025Why Sprouts Farmers Market is Buying $1 Billion of Its Own StockBy Gabriel Osorio-Mazilli | August 25, 2025Brinker Serves Up Earnings Beat, Sidesteps Cost PressuresBy Chris Markoch | August 14, 2025IPHA, NAGE, AVBP, and DAWN Company DescriptionsArriVent BioPharma NASDAQ:AVBP$20.19 +0.67 (+3.43%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$20.16 -0.03 (-0.15%) As of 09/5/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.Day One Biopharmaceuticals NASDAQ:DAWN$7.55 +0.14 (+1.89%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$7.54 -0.01 (-0.08%) As of 09/5/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.Innate Pharma NASDAQ:IPHA$2.00 -0.11 (-5.00%) As of 09/5/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Niagen Bioscience NASDAQ:NAGE$9.41 +0.09 (+0.97%) As of 09/5/2025 04:00 PM EasternNiagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
